Supplementary Figure 2S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

Autor: Timothy Eisen, Örjan Nordle, Goran Forsberg, Gunnar Hedlund, Rustem Khasanov, Oleg Karyakin, Petr Karlov, Igor Bondarenko, Serhii Polenkov, Mihai Harza, Tosho Ganev, Oleg Gladkov, Vladimir Bondar, Yaroslav Shparyk, Martin Gore, Robert E. Hawkins
Rok vydání: 2023
Popis: Anti-SEA/E-120 vs exposure of Nap. Concentration of Nap after Nap at day 1 of treatment. Moving median of 8 overlapping subgroups of patients with different baseline anti-SEA/E-120 (pmol/mL). Median{plus minus}SE is depicted.
Databáze: OpenAIRE